Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$0.2450
-0.00870-3.43%
At close: -
$0.2420
-0.00300-1.22%
After Hours: May 16, 6:55 PM EDT
Comments
Loading...
Cellectar Biosciences Analyst Ratings and Price Targets | NASDAQ:CLRB | Benzinga
Cellectar Biosciences Corp has a consensus price target of $567.61 based on the ratings of 38 analysts. The high is $1350 issued by HSBC on May 10, 2024<. The low is $100 issued by Deutsche Bank on August 5, 2024. The 3 most-recent analyst ratings were released by New Street Research, Goldman Sachs, and Deutsche Bank on August 6, 2024, August 5, 2024, and August 5, 2024, respectively. With an average price target of $118.33 between New Street Research, Goldman Sachs, and Deutsche Bank, there's an implied 0.21% upside for Cellectar Biosciences Corp from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Roth MKM
HC Wainwright & Co.
1calculated from analyst ratings
Analyst Ratings for Cellectar Biosciences
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 05/14/2025 | Buy Now | — | Maxim Group | Jason McCarthy42% | — | Downgrade | Buy → Hold | Get Alert |
| 12/11/2024 | Buy Now | — | Oppenheimer | Jeff Jones33% | — | Downgrade | Outperform → Perform | Get Alert |
| 11/19/2024 | Buy Now | — | Oppenheimer | Jeff Jones33% | $14 → $12 | Maintains | Outperform | Get Alert |
| 10/11/2024 | Buy Now | — | Oppenheimer | Jeff Jones33% | $14 → $14 | Reiterates | Outperform → Outperform | Get Alert |
| 03/28/2024 | Buy Now | — | Roth MKM | Jonathan Aschoff34% | $20 → $28 | Maintains | Buy | Get Alert |
| 03/28/2024 | Buy Now | — | Oppenheimer | Jeff Jones33% | $11 → $12 | Reiterates | Outperform → Outperform | Get Alert |
| 03/04/2024 | Buy Now | — | Roth MKM | Jonathan Aschoff34% | → $20 | Reiterates | Buy → Buy | Get Alert |
| 11/04/2022 | Buy Now | — | HC Wainwright & Co. | Swayampakula Ramakanth50% | $3 → $4 | Maintains | Buy | Get Alert |
| 07/18/2022 | Buy Now | — | Oppenheimer | Jeff Jones33% | → $5.5 | Assumes | → Outperform | Get Alert |
FAQ
What is the target price for Cellectar Biosciences (CLRB) stock?
The latest price target for Cellectar Biosciences (NASDAQ:CLRB) was reported by Maxim Group on May 14, 2025. The analyst firm set a price target for $0.00 expecting CLRB to fall to within 12 months (a possible -100.00% downside). 4 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Cellectar Biosciences (CLRB)?
The latest analyst rating for Cellectar Biosciences (NASDAQ:CLRB) was provided by Maxim Group, and Cellectar Biosciences downgraded their hold rating.
When was the last upgrade for Cellectar Biosciences (CLRB)?
There is no last upgrade for Cellectar Biosciences
When was the last downgrade for Cellectar Biosciences (CLRB)?
The last downgrade for Cellectar Biosciences Inc happened on May 14, 2025 when Maxim Group changed their price target from N/A to N/A for Cellectar Biosciences Inc.
When is the next analyst rating going to be posted or updated for Cellectar Biosciences (CLRB)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Cellectar Biosciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Cellectar Biosciences was filed on May 14, 2025 so you should expect the next rating to be made available sometime around May 14, 2026.
Is the Analyst Rating Cellectar Biosciences (CLRB) correct?
While ratings are subjective and will change, the latest Cellectar Biosciences (CLRB) rating was a downgraded with a price target of $0.00 to $0.00. The current price Cellectar Biosciences (CLRB) is trading at is $0.24, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
